Cencora Raises FY2026 EPS Guidance on Share Buybacks
Event summary
- Cencora updated its FY2026 adjusted diluted EPS guidance to $17.70–$17.90, up from $17.65–$17.90, due to recent share repurchases.
- The company completed opportunistic share repurchases in May 2026, aligning with its $1.0 billion buyback target by year-end.
- Cencora’s Board authorized a new $2.0 billion share repurchase program on May 20, 2026, with $382 million remaining from the prior authorization.
- Cencora ranks #10 on the Fortune 500 and #18 on the Global Fortune 500, with over $300 billion in annual revenue.
The big picture
Cencora’s updated guidance reflects aggressive capital returns, a trend among large-cap pharma firms optimizing shareholder value. The move underscores confidence in cash flow stability, though investors will scrutinize whether buybacks outweigh reinvestment in innovation or M&A. With $300B+ in revenue, Cencora’s actions signal a broader industry shift toward financial discipline amid regulatory and pricing pressures.
What we're watching
- Capital Allocation Strategy
- How Cencora balances share buybacks with other growth initiatives amid its $300B+ revenue scale.
- Market Conditions
- Whether the new $2.0B repurchase program will be fully utilized given volatility.
- Earnings Momentum
- The pace at which adjusted EPS growth accelerates beyond the updated guidance.
Related topics